# NOVAVAX INC > Alpha governed public record. Unknown, unavailable, and unpublished values are never inferred as zero. ## Record | Field | Value | | --- | --- | | Representation | alpha-profile-markdown-v4 | | Protocol | Alpha Governance Facts Protocol 0.1 | | Schema | alpha.governance.entity.public.v1 | | Record version | public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce | | Governance record representation | alpha-governance-record-v2 | | Canonical entity | alpha:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5 | | Entity type | Company | | Canonical URL | https://registry.alpha.ac/companies/novavax-inc | | Publication | PUBLISHED | | Verification | source_reported | | Verification schema | alpha-verification-states-v1 | | Ownership | unclaimed | | Published claims | 27 | | Claims under review | 1 | | Evidence records | 7 | | Conflicts | 0 | | Conflicts in internal review | 0 | | Observed | 2026-10-18T07:11:51.27144+00:00 | | Last reviewed | 2026-10-18T07:11:51.27144+00:00 | ## Identity - Legal name: NOVAVAX INC - Display name: NOVAVAX INC ## Alpha Governance Record | Field | Value | | --- | --- | | Governance Record schema | alpha-governance-record-v2 | | Ontology | alpha-governance-ontology-v1 | | Record version | public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce | | As of | 2026-10-19T01:18:05.33066+00:00 | | Completeness | 0.364 | | Record Quality | 0.834 | | Directors | 15 | | Committees | 0 | | Governance events | 11 | | Entity class | public_company | ## Section coverage | Section | State | | --- | --- | | identity | PUBLISHED | | corporate_structure | NOT_REVIEWED | | board | PUBLISHED | | committees | NOT_REVIEWED | | leadership | PUBLISHED | | ownership | NOT_REVIEWED | | financials | NOT_REVIEWED | | capital_structure | PUBLISHED | | compensation | NOT_REVIEWED | | governance | NOT_REVIEWED | | shareholder_governance | NOT_REVIEWED | | audit | NOT_REVIEWED | | legal | NOT_REVIEWED | | risk | NOT_REVIEWED | | cyber | NOT_REVIEWED | | ai_governance | NOT_REVIEWED | | agent_governance | RESTRICTED | | markets_external | NOT_REVIEWED | | events | PUBLISHED | | relationships | PUBLISHED | | assessments | PUBLISHED | | evidence | PUBLISHED | ## Board - Alderya Therapeutics: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2020-01-01. claim_id=alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:6 - Amicus Therapeutics: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2020-01-01. claim_id=alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:7 - AuraVax Therapeutics: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2025-01-01. claim_id=alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:8 - Brii Biosciences: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2022-01-01. claim_id=alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:9 - Charles W. Newton: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2023-01-01. claim_id=alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:10 - Maryland Life Sciences Advisory: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2025-01-01. claim_id=alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:15 - Opus Genetics: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2010-01-01. claim_id=alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:16 - David Mott: Chairman of the Board. Status: unknown. Independent: true. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:5 - Gregg H. Alton: Director. Status: unknown. Independent: true. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:11 - John C. Jacobs: President and Chief Executive Officer. Status: unknown. Independent: false. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:12 - John W. Shiver: Director. Status: unknown. Independent: true. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:13 - Margaret G. McGlynn: Director. Status: unknown. Independent: true. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:14 - Rachel K. King: Director. Status: unknown. Independent: true. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:17 - Richard H. Douglas: Director. Status: unknown. Independent: true. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:18 - Richard J. Rodgers: Director. Status: unknown. Independent: true. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:19 ## Executive leadership - Jeffrey D. Kelly: Named Executive Officer. Status: current. claim_id=alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:22 - John Trizzino: Named Executive Officer. Status: current. claim_id=alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:24 - Michael Casey: Executive Vice President, Chief Legal Officer and Corporate Secretary [GC]. Status: current. claim_id=alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:26 - Ruxandra Draghia-Akli: Named Executive Officer. Status: current. claim_id=alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:27 - Elaine O'Hara: Executive Vice President, Chief Strategy Officer. Status: unknown. claim_id=alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:20 - James P. Kelly: Executive Vice President, Chief Financial Officer and Treasurer [CFO]. Status: unknown. claim_id=alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:21 - John C. Jacobs: President and Chief Executive Officer [CEO]. Status: unknown. claim_id=alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:23 - Mark J. Casey: Executive Vice President, Chief Legal Officer and Corporate Secretary [GC]. Status: unknown. claim_id=alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:25 ## Governance events - EXECUTIVE_APPOINTED: Jeffrey D. Kelly executive of NOVAVAX INC, effective 2026-04-27. Effective: 2026-04-27. Detected: 2026-10-18T07:11:51.27144+00:00. event_id=alpha:event:transition:74ni8m19i2hyo - EXECUTIVE_APPOINTED: John Trizzino executive of NOVAVAX INC, effective 2026-04-27. Effective: 2026-04-27. Detected: 2026-10-18T07:11:51.27144+00:00. event_id=alpha:event:transition:yb8hap143b87h - GC_CHANGED: Michael Casey executive of NOVAVAX INC, effective 2026-04-27. Effective: 2026-04-27. Detected: 2026-10-18T07:11:51.27144+00:00. event_id=alpha:event:transition:1xq31k511g273d - EXECUTIVE_APPOINTED: Ruxandra Draghia-Akli executive of NOVAVAX INC, effective 2026-04-27. Effective: 2026-04-27. Detected: 2026-10-18T07:11:51.27144+00:00. event_id=alpha:event:transition:36tyri18kk6no - DIRECTOR_APPOINTED: AuraVax Therapeutics seat on NOVAVAX INC, effective 2025-01-01. Effective: 2025-01-01. Detected: 2026-10-18T07:11:51.27144+00:00. event_id=alpha:event:transition:13e8agm146b7v6 - DIRECTOR_APPOINTED: Maryland Life Sciences Advisory seat on NOVAVAX INC, effective 2025-01-01. Effective: 2025-01-01. Detected: 2026-10-18T07:11:51.27144+00:00. event_id=alpha:event:transition:99s4skzadnuy - DIRECTOR_APPOINTED: Charles W. Newton seat on NOVAVAX INC, effective 2023-01-01. Effective: 2023-01-01. Detected: 2026-10-18T07:11:51.27144+00:00. event_id=alpha:event:transition:1ih5pdt1ckth31 - DIRECTOR_APPOINTED: Brii Biosciences seat on NOVAVAX INC, effective 2022-01-01. Effective: 2022-01-01. Detected: 2026-10-18T07:11:51.27144+00:00. event_id=alpha:event:transition:1fg6ha8u2c85w - DIRECTOR_APPOINTED: Alderya Therapeutics seat on NOVAVAX INC, effective 2020-01-01. Effective: 2020-01-01. Detected: 2026-10-18T07:11:51.27144+00:00. event_id=alpha:event:transition:tix9sj1uxmrn1 - DIRECTOR_APPOINTED: Amicus Therapeutics seat on NOVAVAX INC, effective 2020-01-01. Effective: 2020-01-01. Detected: 2026-10-18T07:11:51.27144+00:00. event_id=alpha:event:transition:htvola1kifn3o - DIRECTOR_APPOINTED: Opus Genetics seat on NOVAVAX INC, effective 2010-01-01. Effective: 2010-01-01. Detected: 2026-10-18T07:11:51.27144+00:00. event_id=alpha:event:transition:17sg07dglimx3 ## Scoped resources - `alpha://company/novavax-inc` (contract): https://registry.alpha.ac/api/public/companies/novavax-inc?format=record - `alpha://company/novavax-inc/identity` (contract): https://registry.alpha.ac/api/public/companies/novavax-inc?format=record§ion=identity - `alpha://company/novavax-inc/corporate-structure` (contract): https://registry.alpha.ac/api/public/companies/novavax-inc?format=record§ion=corporate-structure - `alpha://company/novavax-inc/board` (contract): https://registry.alpha.ac/api/public/companies/novavax-inc?format=record§ion=board - `alpha://company/novavax-inc/committees` (contract): https://registry.alpha.ac/api/public/companies/novavax-inc?format=record§ion=committees - `alpha://company/novavax-inc/leadership` (contract): https://registry.alpha.ac/api/public/companies/novavax-inc?format=record§ion=leadership - `alpha://company/novavax-inc/ownership` (contract): https://registry.alpha.ac/api/public/companies/novavax-inc?format=record§ion=ownership - `alpha://company/novavax-inc/financials` (contract): https://registry.alpha.ac/api/public/companies/novavax-inc?format=record§ion=financials - `alpha://company/novavax-inc/capital-structure` (contract): https://registry.alpha.ac/api/public/companies/novavax-inc?format=record§ion=capital-structure - `alpha://company/novavax-inc/compensation` (contract): https://registry.alpha.ac/api/public/companies/novavax-inc?format=record§ion=compensation - `alpha://company/novavax-inc/governance` (contract): https://registry.alpha.ac/api/public/companies/novavax-inc?format=record§ion=governance - `alpha://company/novavax-inc/shareholder-governance` (contract): https://registry.alpha.ac/api/public/companies/novavax-inc?format=record§ion=shareholder-governance - `alpha://company/novavax-inc/audit` (contract): https://registry.alpha.ac/api/public/companies/novavax-inc?format=record§ion=audit - `alpha://company/novavax-inc/legal` (contract): https://registry.alpha.ac/api/public/companies/novavax-inc?format=record§ion=legal - `alpha://company/novavax-inc/risk` (contract): https://registry.alpha.ac/api/public/companies/novavax-inc?format=record§ion=risk - `alpha://company/novavax-inc/cyber` (contract): https://registry.alpha.ac/api/public/companies/novavax-inc?format=record§ion=cyber - `alpha://company/novavax-inc/ai-governance` (contract): https://registry.alpha.ac/api/public/companies/novavax-inc?format=record§ion=ai-governance - `alpha://company/novavax-inc/agents` (contract): https://registry.alpha.ac/api/public/companies/novavax-inc?format=record§ion=agents - `alpha://company/novavax-inc/ecosystem` (contract): https://registry.alpha.ac/api/public/companies/novavax-inc?format=record§ion=ecosystem - `alpha://company/novavax-inc/events` (contract): https://registry.alpha.ac/api/public/companies/novavax-inc?format=record§ion=events - `alpha://company/novavax-inc/relationships` (contract): https://registry.alpha.ac/api/public/companies/novavax-inc?format=record§ion=relationships - `alpha://company/novavax-inc/assessments` (contract): https://registry.alpha.ac/api/public/companies/novavax-inc?format=record§ion=assessments - `alpha://company/novavax-inc/evidence` (contract): https://registry.alpha.ac/api/public/companies/novavax-inc?format=record§ion=evidence ## Role modules - NOT_ASSERTED ## Attention - NO_RECORDS_FOUND ## Committee data - NO_RECORDS_FOUND ## Leadership - David Mott: Chairman of the Board. Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:5. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:ff32d70e8a9b64b3c7d1001af6936750d20ffffcdbdcf3ff3fe14e3618bc587e. - Alderya Therapeutics: Director. Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:6. Valid from: 2020-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:175d30715a6589cc3390c7c5ef5468d1daa3d6d31474b1cf67fdbf78252d35bf. - Amicus Therapeutics: Director. Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:7. Valid from: 2020-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:175d30715a6589cc3390c7c5ef5468d1daa3d6d31474b1cf67fdbf78252d35bf. - AuraVax Therapeutics: Director. Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:8. Valid from: 2025-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:175d30715a6589cc3390c7c5ef5468d1daa3d6d31474b1cf67fdbf78252d35bf. - Brii Biosciences: Director. Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:9. Valid from: 2022-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:175d30715a6589cc3390c7c5ef5468d1daa3d6d31474b1cf67fdbf78252d35bf. - Charles W. Newton: Director. Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:10. Valid from: 2023-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:175d30715a6589cc3390c7c5ef5468d1daa3d6d31474b1cf67fdbf78252d35bf. - Gregg H. Alton: Director. Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:11. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:ff32d70e8a9b64b3c7d1001af6936750d20ffffcdbdcf3ff3fe14e3618bc587e. - John C. Jacobs: President and Chief Executive Officer. Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:12. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:ff32d70e8a9b64b3c7d1001af6936750d20ffffcdbdcf3ff3fe14e3618bc587e. - John W. Shiver: Director. Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:13. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:ff32d70e8a9b64b3c7d1001af6936750d20ffffcdbdcf3ff3fe14e3618bc587e. - Margaret G. McGlynn: Director. Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:14. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:ff32d70e8a9b64b3c7d1001af6936750d20ffffcdbdcf3ff3fe14e3618bc587e. - Maryland Life Sciences Advisory: Director. Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:15. Valid from: 2025-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:175d30715a6589cc3390c7c5ef5468d1daa3d6d31474b1cf67fdbf78252d35bf. - Opus Genetics: Director. Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:16. Valid from: 2010-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:175d30715a6589cc3390c7c5ef5468d1daa3d6d31474b1cf67fdbf78252d35bf. - Rachel K. King: Director. Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:17. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:ff32d70e8a9b64b3c7d1001af6936750d20ffffcdbdcf3ff3fe14e3618bc587e. - Richard H. Douglas: Director. Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:18. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:ff32d70e8a9b64b3c7d1001af6936750d20ffffcdbdcf3ff3fe14e3618bc587e. - Richard J. Rodgers: Director. Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:19. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:ff32d70e8a9b64b3c7d1001af6936750d20ffffcdbdcf3ff3fe14e3618bc587e. - Elaine O'Hara: Executive Vice President, Chief Strategy Officer. Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:20. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:ff32d70e8a9b64b3c7d1001af6936750d20ffffcdbdcf3ff3fe14e3618bc587e. - James P. Kelly: Executive Vice President, Chief Financial Officer and Treasurer. Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:21. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:ff32d70e8a9b64b3c7d1001af6936750d20ffffcdbdcf3ff3fe14e3618bc587e. - Jeffrey D. Kelly: Named Executive Officer. Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:22. Valid from: 2026-04-27. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:f037cb8859aa9e25095f29e05764b56b10350ab06f66b8c57eadc9c4f7908255. - John C. Jacobs: President and Chief Executive Officer. Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:23. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:ff32d70e8a9b64b3c7d1001af6936750d20ffffcdbdcf3ff3fe14e3618bc587e. - John Trizzino: Named Executive Officer. Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:24. Valid from: 2026-04-27. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:a36ac2691aed7a3541ac0f69a3e80a59a885ba87b4e8c70f9ebaf3fae39fdcff. - Mark J. Casey: Executive Vice President, Chief Legal Officer and Corporate Secretary. Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:25. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:ff32d70e8a9b64b3c7d1001af6936750d20ffffcdbdcf3ff3fe14e3618bc587e. - Michael Casey: Executive Vice President, Chief Legal Officer and Corporate Secretary. Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:26. Valid from: 2026-04-27. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:61de0a12d94edbeccc0e88cc44025f89f3babb4f66743bdee16ded6b590ccf32. - Ruxandra Draghia-Akli: Named Executive Officer. Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:leadership_role:27. Valid from: 2026-04-27. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:c77f87bd20375542c8cddf23567e8e094e3888e4abe3c6f916a0fe7a84b07fb6. ## Roles - PUBLISHED ## Governance - NOT_ASSERTED ## Board committees - PUBLISHED ## Financials - NOT_ASSERTED ## Workforce - NOT_ASSERTED ## Market and index context - PUBLISHED ## Legal Name - NOVAVAX INC. Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:legal_name:1. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:aaba89d0b8152956a4dcf78014b32fd333b2455b79c707990ab17b29bd12a791. ## Entity Status - Public listing published. Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:entity_status:3. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:aaba89d0b8152956a4dcf78014b32fd333b2455b79c707990ab17b29bd12a791. ## Published Fact - US. Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:published_fact:4. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:aaba89d0b8152956a4dcf78014b32fd333b2455b79c707990ab17b29bd12a791. ## Security Listing - NVAX (NASDAQ). Claim: alpha:claim:company:bab98dd4-6f6e-46f5-98b9-c2925f0b89c5:security_listing:28. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:aaba89d0b8152956a4dcf78014b32fd333b2455b79c707990ab17b29bd12a791. ## Coverage states | Field | Value | | --- | --- | | Identity | PUBLISHED | | Business | PUBLISHED | | Leadership | PUBLISHED | | Board and committees | PUBLISHED | | Governance | NOT_ASSERTED | | Financials | NOT_ASSERTED | | Workforce | NOT_ASSERTED | | Ownership | NOT_ASSERTED | | Ratings | NOT_PUBLISHED | | Market and index context | PUBLISHED | ## Public sources - alpha:projection-evidence:aaba89d0b8152956a4dcf78014b32fd333b2455b79c707990ab17b29bd12a791: [Alpha canonical company public projection](https://www.alpha.ac/api/public/companies/novavax-inc). - alpha:projection-evidence:document:ff32d70e8a9b64b3c7d1001af6936750d20ffffcdbdcf3ff3fe14e3618bc587e: [SEC DEF 14A 0001628280-26-027328](https://www.sec.gov/Archives/edgar/data/1000694/000162828026027328/nvax-20260427.htm). - alpha:projection-evidence:document:175d30715a6589cc3390c7c5ef5468d1daa3d6d31474b1cf67fdbf78252d35bf: [DEF 14A nvax-20260427.htm](https://www.sec.gov/Archives/edgar/data/1000694/000162828026027328/nvax-20260427.htm). - alpha:projection-evidence:document:f037cb8859aa9e25095f29e05764b56b10350ab06f66b8c57eadc9c4f7908255: [NVAX DEF 14A executive officers](https://www.sec.gov/Archives/edgar/data/1000694/000162828026027328/nvax-20260427.htm). - alpha:projection-evidence:document:a36ac2691aed7a3541ac0f69a3e80a59a885ba87b4e8c70f9ebaf3fae39fdcff: [NVAX DEF 14A executive officers](https://www.sec.gov/Archives/edgar/data/1000694/000162828026027328/nvax-20260427.htm). - alpha:projection-evidence:document:61de0a12d94edbeccc0e88cc44025f89f3babb4f66743bdee16ded6b590ccf32: [NVAX DEF 14A executive officers](https://www.sec.gov/Archives/edgar/data/1000694/000162828026027328/nvax-20260427.htm). - alpha:projection-evidence:document:c77f87bd20375542c8cddf23567e8e094e3888e4abe3c6f916a0fe7a84b07fb6: [NVAX DEF 14A executive officers](https://www.sec.gov/Archives/edgar/data/1000694/000162828026027328/nvax-20260427.htm). ## Rights | Field | Value | | --- | --- | | public_retrieval | allowed | | agent_retrieval | allowed | | redistribution | not_granted | | model_training | not_granted | | commercial_use | not_specified | | relationship_pathfinding | not_granted | | direct_contact | not_granted | ## Limitations - Absence of a leadership role, committee, or disclosure is not evidence that it does not exist. - Only explicitly published canonical company identity and current confirmed public roles are included. - Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist. - Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights. - This Company Profile is an identity and evidence record, not an Alpha rating. ## Alternate representations - [Canonical profile](https://registry.alpha.ac/companies/novavax-inc) - [Public Markdown](https://registry.alpha.ac/companies/novavax-inc.md) - [Public JSON](https://registry.alpha.ac/api/public/companies/novavax-inc?format=record) - [JSON-LD](https://registry.alpha.ac/api/public/companies/novavax-inc?format=jsonld) - MCP resource: `alpha://companies/novavax-inc` at https://mcp.alpha.ac/mcp ## Connected governance records Only explicitly published, rights-cleared records. Missing records do not establish absence, safety, or complete coverage. ## Critical-risk oversight Snapshot as of 2026-10-19T01:18:05.087771+00:00; recorded 2026-10-19T01:18:05.087771+00:00. Every published assignment for this snapshot is listed. Only explicitly reviewed, rights-cleared assignments in effect on the as-of date, in the company's own wording. An assignment shows where oversight is placed, not whether it is effective. Missing records do not establish absence.